glp-1 weight loss clinical trials GLP-1R Agonists for GLP-1 anti-obesity drugs lead to

Despite demonstrating robust glycemic efficacy, both agents were eventually discontinued due to distinct tolerability and safety concerns, diverging in severity and clinical implications

Research on obese mice suggests that unimolecular poly-pharmacology is an effective means to deal with various mechanisms leading to obesity and further indicates that GCGR activation is the distinguishing factor between single or double agonists and triple agonists of incretin receptors (127)

It's regulated under DSHEA, not the FDA drug approval pathway

What they do is bring an out-of-control appetite back into a more normal range so people can make healthier choices

Maghrabi, A

Journal of Cutaneous Medicine and Surgery